Marriott Harrison advises on AIM IPO of SalvaRx Group PLC

Friday 1st April, 2016

Corporate partner Simon Charles and corporate associate David Bettis advised Northland Capital Partners Limited in its capacity as nominated adviser and broker to SalvarRx Group PLC, a drug discovery and development company which focuses on immuno oncology and which invests in novel cancer immuno-therapies, on its admission to AIM and related equity issue.

MH Corporate